Key facts
- a:head Bio’s last known valuation is $3.8M (Aug 2019).
- It has raised $1.7M; the latest was Later Stage VC in Apr 2025.
- Notable investors include The Austrian Research Promotion Agency, red-stars.com data.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for a:head Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for a:head Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About a:head Bio
Developer of novel drugs intended for treating brain disorders based on human cerebral organoids. The company develops 3D tissue cultures from human stem cells through in vitro experiments to understand the brain's developmental processes, enabling healthcare professionals to improve the quality of life of patients suffering from central nervous system diseases.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2019
- Employees
- 19
- Website
- aheadbio.com/
- Ownership
- Privately Held (backing)
a:head Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in a:head Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on a:head Bio in its N-PORT filings yet. We sweep new filings monthly.